The efficacy of molnupiravir in patients with COVID-19

Comparing the efficacy of Molnupiravir and placebo on recovery rate in patients with mild COVID-19, a randomized multicenter clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210914052480N2

Enrollment

500

Registered

2022-07-07

Start date

2022-04-21

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: The group receiving oral molnopiravir 200 mg daily for up to five days after the intervention, with diphenhydramine syrup / vitamin C tablet / vitamin D tablet / fa

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Living in a family with at least one infected person with COVID-19 Not having pulmonary involvement Not having symptoms like chest wall pain and dysnea suggesting pulmonary involvement Positive PCR test of COVID-19 Patient with COVID-19 symptoms lesser than 3 days Patients satisfied with consumption of oral medication Blood oxygen saturation above 93 percents

Exclusion criteria

Exclusion criteria: Patients under 18 years old Having underlying diseases such as uncontrolled diabetes, uncontrolled blood pressure, liver and heart disease and kidney, heart and liver failure History of any of the diseases including hepatitis B or C, HIV, autoimmune diseases and immunodeficiency History of hepatocellular disease, liver failure and heart failure of liver tests more than 3 times normal History of allergy to antiviral drugs Existence of thrombocytopenia (platelets under 100000) History of recent COVID-19 vaccination lesser than 7 days being pregnant breastfeeding

Design outcomes

Primary

Measure	Time frame
Negative pcr test or increase in CT NUMBER after intervention. Timepoint: Before and after the intervention. Method of measurement: According to the throat sample of patients with Covid-19, which is taken from patients in the same conditions in the specialized virology laboratory of Baqiyatallah Medical Center.;Fever. Timepoint: Upon arrival and after five days. Method of measurement: with a standard thermometer.;Serum CRP inflammatory factor. Timepoint: Upon arrival and after five days. Method of measurement: By a valid laboratory.;The level of oxygen saturation in the blood of patients. Timepoint: Upon arrival and after five days. Method of measurement: By standard pulse oximeter.;Dry cough existance. Timepoint: Upon arrival and after five days. Method of measurement: patient report and researcher observe.;Dyspnea. Timepoint: Upon arrival and after five days. Method of measurement: patient report and researcher observe.;Muscular pain. Timepoint: Upon arrival and after five days. Method of measurement: patient report and researcher observe.;Pulse rate. Timepoint: Upon arrival and after five days. Method of measurement: researcher measure.;Respiratory rate. Timepoint: Upon arrival and after five days. Method of measurement: researcher measure.;Blood pressure. Timepoint: Upon arrival and after five days. Method of measurement: researcher measure.;Serum ESR inflammatory factor. Timepoint: Upon arrival and after five days. Method of measurement: By a valid laboratory.	—

Measure

Time frame

Negative pcr test or increase in CT NUMBER after intervention. Timepoint: Before and after the intervention. Method of measurement: According to the throat sample of patients with Covid-19, which is taken from patients in the same conditions in the specialized virology laboratory of Baqiyatallah Medical Center.;Fever. Timepoint: Upon arrival and after five days. Method of measurement: with a standard thermometer.;Serum CRP inflammatory factor. Timepoint: Upon arrival and after five days. Method of measurement: By a valid laboratory.;The level of oxygen saturation in the blood of patients. Timepoint: Upon arrival and after five days. Method of measurement: By standard pulse oximeter.;Dry cough existance. Timepoint: Upon arrival and after five days. Method of measurement: patient report and researcher observe.;Dyspnea. Timepoint: Upon arrival and after five days. Method of measurement: patient report and researcher observe.;Muscular pain. Timepoint: Upon arrival and after five days. Method of measurement: patient report and researcher observe.;Pulse rate. Timepoint: Upon arrival and after five days. Method of measurement: researcher measure.;Respiratory rate. Timepoint: Upon arrival and after five days. Method of measurement: researcher measure.;Blood pressure. Timepoint: Upon arrival and after five days. Method of measurement: researcher measure.;Serum ESR inflammatory factor. Timepoint: Upon arrival and after five days. Method of measurement: By a valid laboratory.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Soleymanitabar

Bagheiat-allah University of Medical Sciences

Asoleimanitabar21@gmail.com+98 21 8860 0067

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026